Profitability improved as the company delivered its first full year of positive Adjusted EBITDA. Gross margin was 79% in the fourth quarter and 79.6% for the full year, with Maheshwari noting the full-year gross margin came in about 200 basis points above the company’s original 2025 guidance. He attributed the outperformance to stable average selling prices from favorable procedure mix and to operational initiatives such as supply chain efficiency and cost optimization.For the full year 2025, worldwide reve ...

Core Insights - SI-BONE, Inc. will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, with a management-hosted fireside chat [1] - The company is a leader in developing technologies for surgical treatment of sacropelvic disorders, having supported over 4,900 physicians and performed over 135,000 procedures since 2009 [3] Company Overview - SI-BONE, Inc. specializes in minimally invasive SI joint surgery, having pioneered the iFuse Implant System [3] - The company has a strong clinical foundation with over 180 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity and pelvic trauma [3] Conference Participation - Investors can register to listen to the conference call and access a live audio webcast on the company's website [2] - The webcast will be archived for at least 90 days post-event [2]

Core Insights - SI-BONE, Inc. reported a strong financial performance in Q3 2025, with worldwide revenue growth of approximately 21% and a positive adjusted EBITDA margin of $2.3 million, indicating robust demand for its medical devices [1][7][8]. Financial Performance - Worldwide revenue reached $48.7 million, a 20.6% increase from $40.3 million in Q3 2024 [4][8]. - U.S. revenue was $46.4 million, reflecting a 21.2% increase from $38.3 million in the same period last year, driven by strong procedure demand [4][8]. - International revenue was $2.3 million, a 10.2% increase from $2.1 million in Q3 2024, attributed to the successful launch of the TORQ product in European markets [4][8]. Profitability Metrics - Gross profit for the quarter was $38.8 million, up 21.8% from $31.9 million in Q3 2024, with a gross margin of 79.8%, an improvement of 75 basis points year-over-year [5][8]. - Operating expenses increased by 11.9% to $44.2 million, primarily due to higher commercial activities and new product rollouts [6][8]. - The operating loss improved by 29.5% to $5.4 million compared to a loss of $7.6 million in Q3 2024 [6][8]. Net Loss and Cash Flow - The net loss for the quarter was $4.6 million, or $0.11 per diluted share, an improvement of 30.6% from a net loss of $6.6 million, or $0.16 per diluted share, in Q3 2024 [7][8]. - Positive cash from operating activities was reported at $2.3 million, indicating effective cash management [8]. Guidance and Future Outlook - For fiscal 2025, SI-BONE expects worldwide revenue to be between $198 million and $200 million, representing year-over-year growth of approximately 18% to 20% [10][11]. - The company anticipates a gross margin of around 79.5% for the full year 2025, reflecting continued operational efficiency [10][11]. Operational Highlights - The number of active U.S. physicians increased by 27% to 1,530, indicating growing adoption of SI-BONE's technologies [8]. - The trailing 12-month average revenue per territory rose by 16% to $2.1 million, showcasing improved sales performance [8].

Core Insights - SI-BONE, Inc. will report its financial results for Q3 2025 on November 10, 2025, after market close [1] - A conference call will be held at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the results [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,600 physicians in performing nearly 130,000 procedures, backed by over 175 peer-reviewed publications, including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Company Participation - SI-BONE, Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9, 2025 [1] - Management will host a fireside chat at 4:00 a.m. Pacific Time / 07:00 a.m. Eastern Time [1] Investor Information - Investors can register for the conference call via a provided link and access the live audio webcast on the company's website [2] - The webcast will be archived for at least 90 days post-event [2] Company Overview - SI-BONE is a leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,600 physicians in nearly 130,000 procedures, backed by over 175 peer-reviewed publications including four randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets such as adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]

Core Viewpoint - SI-BONE, Inc. is set to report its financial results for Q2 2025 on August 4, 2025, with a conference call scheduled for the same day [1]. Company Overview - SI-BONE, Inc. is a leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3]. - The company has supported over 4,500 physicians in performing more than 125,000 procedures, backed by over 175 peer-reviewed publications, including two randomized controlled trials [3]. - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3].

Company Overview - SI-BONE, Inc. is a medical device company focused on addressing sacropelvic disorders and is recognized as a global leader in developing innovative surgical technologies [3] - The company pioneered minimally invasive SI joint surgery in 2009 with the introduction of the iFuse Implant System, supporting over 4,500 physicians and facilitating more than 120,000 procedures [3] - SI-BONE has established a strong clinical foundation with over 160 peer-reviewed publications, including two randomized controlled trials, validating the effectiveness of its technologies [3] Upcoming Event - SI-BONE will participate in the 2025 Truist Securities MedTech Conference in Boston, MA, with a fireside chat scheduled for June 17, 2025, at 10:00 a.m. Pacific Time [1] - Investors can register for the conference call and access a live audio webcast on the company's website, which will be archived for at least 90 days post-event [2]

Company Participation - SI-BONE, Inc. will participate in the 2025 Goldman Sachs 46 Global Healthcare Conference in Miami Beach, FL, hosting a fireside chat on June 10, 2025, at 8:20 a.m. Pacific Time [1] Company Overview - SI-BONE is a global leader in developing technologies for surgical treatment of sacropelvic disorders, having pioneered minimally invasive SI joint surgery in 2009 with the iFuse Implant System [3] - The company has supported over 4,500 physicians in performing more than 120,000 procedures, backed by over 160 peer-reviewed publications, including two randomized controlled trials [3] - SI-BONE has expanded its offerings to adjacent markets, including adult deformity, spinopelvic and sacropelvic fixation, and pelvic trauma [3]